Tourmaline Bio enhances severance benefits for CFO and CBO in change-in-control scenarios

Tourmaline Bio, Inc.

Board amended Severance Plan on Sep 8, 2025 for CFO Ryan Robinson and CBO Brad Middlekauff.
Qualifying termination within 3 months before or 12 months after change-in-control triggers lump sum of 15 months salary plus 125% target bonus.
Also entitled to COBRA premium reimbursement for up to 15 months and 100% acceleration of time-based equity awards.
CEO Sandeep Kulkarni's severance benefits remain unchanged.

item 5.02

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.